Rh incompatibility

Rh incompatibility
OpenStax College · CC BY 3.0 · source
Name	Rh incompatibility
Field	Hematology, Obstetrics
Symptoms	Anemia, jaundice, hydrops fetalis
Complications	Kernicterus, stillbirth
Onset	Pregnancy
Causes	Maternal anti-D alloimmunization
Diagnosis	Indirect Coombs test, fetal middle cerebral artery Doppler
Prevention	Anti-D immunoglobulin (Rho(D) immune globulin)
Treatment	Intrauterine transfusion, phototherapy, exchange transfusion

Rh incompatibility

Rh incompatibility is an alloimmune condition in obstetrics in which maternal antibodies directed against fetal red blood cell antigens lead to hemolytic disease of the fetus and newborn. It involves a cascade of immunologic, hematologic, and fetal hemodynamic events that can culminate in anemia, hydrops fetalis, and perinatal mortality without appropriate surveillance and intervention. Management spans prenatal screening, immunoprophylaxis, and fetal or neonatal therapy coordinated among specialists in obstetrics, hematology, neonatology, and transfusion medicine.

Overview

Rh incompatibility arises when an Rh-negative mother is exposed to Rh-positive fetal red blood cells, provoking an immune response that generates IgG anti-D antibodies capable of crossing the placenta. This mechanism is analogous to other maternal alloimmune disorders encountered in perinatal medicine and is monitored within antenatal care pathways used by institutions such as World Health Organization, Centers for Disease Control and Prevention, Royal College of Obstetricians and Gynaecologists, American College of Obstetricians and Gynecologists, and national screening programs in countries like United Kingdom and United States. Screening strategies employ serologic assays developed through work at laboratories affiliated with universities including Johns Hopkins University, Harvard University, University of Oxford, University of Cambridge, and research centers such as Mayo Clinic and Cleveland Clinic.

Pathophysiology

Fetomaternal hemorrhage exposes maternal immune system components in lymphoid tissues such as Walter Reed National Military Medical Center–level immunology laboratories to fetal Rh(D) antigen, initiating a primary IgM response and, on subsequent exposures, a memory B cell–driven IgG response. The IgG subclass crosses the placenta via neonatal Fc receptor pathways characterized in studies at National Institutes of Health and binds to fetal erythrocytes, promoting opsonization and destruction in fetal spleen and reticuloendothelial systems similar to mechanisms investigated in immunology departments at Rockefeller University and Karolinska Institutet. Resultant fetal anemia reduces oxygen-carrying capacity and triggers high-output cardiac failure, leading to hydrops fetalis, a syndrome described in case series from centers like Great Ormond Street Hospital and Massachusetts General Hospital.

Clinical Presentation and Diagnosis

Clinically affected fetuses may develop signs detectable by imaging and lab studies utilized by perinatal specialists at institutions such as Fetal Therapy Center (UCSF), Texas Children's Hospital, and Uppsala University Hospital. Ultrasound features include ascites, skin edema, placental thickening, and polyhydramnios; Doppler interrogation of the fetal middle cerebral artery, a technique refined by researchers at Erasmus Medical Center, can noninvasively estimate fetal anemia. Maternal serology employs the indirect antiglobulin (Coombs) test standardized in transfusion services at centers including American Red Cross, NHS Blood and Transplant, and Canadian Blood Services. Neonatal manifestations—jaundice, hemolysis, hepatosplenomegaly—are treated following protocols informed by neonatology groups at Children's Hospital of Philadelphia and Boston Children's Hospital.

Prevention and Management

Prevention centers on antenatal administration of anti-D immunoglobulin (Rho(D) immune globulin) to Rh-negative mothers after potential sensitizing events and at routine gestational intervals, a practice introduced through clinical trials and public health policies involving stakeholders such as Nobel Prize in Physiology or Medicine–winning researchers in immunohematology, and implemented by health services like United Kingdom National Health Service, Centers for Medicare & Medicaid Services, and national perinatal programs in Australia and Canada. Management of an alloimmunized pregnancy involves serial antibody titers, middle cerebral artery Doppler surveillance, and interventions including intrauterine transfusion performed at specialized centers such as Karolinska University Hospital and Hospital Sant Joan de Déu. Neonatal care may require phototherapy, intravenous immunoglobulin, and exchange transfusion following guidelines from organizations like American Academy of Pediatrics and European Society for Pediatric Research.

Epidemiology and Risk Factors

The prevalence of D antigen negativity varies by population, with higher frequencies in populations studied by geneticists at institutions such as Wellcome Trust Sanger Institute, Max Planck Institute for Evolutionary Anthropology, Institute Pasteur, Chinese Academy of Sciences, and population surveys in regions including Sub-Saharan Africa, Europe, East Asia, and South America. Risk factors for sensitization include obstetric events cataloged in textbooks used at Johns Hopkins Hospital and cases managed at referral centers like Karolinska University Hospital: previous pregnancy with an Rh-positive fetus, obstetric procedures (amniocentesis, chorionic villus sampling) performed in tertiary units such as Cleveland Clinic, cesarean delivery, and transfusion of Rh-positive blood documented in transfusion services like American Red Cross. Public health screening programs led by agencies including World Health Organization and Pan American Health Organization track incidence and outcomes.

History and Society

The discovery and mitigation of Rh-related hemolytic disease involved contributions from investigators and clinicians associated with institutions such as Columbia University, University of Pennsylvania, St Thomas' Hospital, and researchers like those honored by awards from Royal Society and medical prizes. Landmark advances included serologic methods and development of rhesus immune globulin products manufactured by pharmaceutical companies and distributed through health systems such as National Health Service and Medicare. Social and ethical dimensions—maternal consent for prophylaxis, allocation of blood products, and perinatal equity—are addressed in policy analyses from bodies like United Nations, European Commission, and bioethics centers at Georgetown University and Harvard Medical School. Historic case reports and public health campaigns documented in archives at Wellcome Library, National Library of Medicine, and major medical journals shaped contemporary obstetric practice worldwide.

Category:Obstetrics